Anti-mitochondrial antibodies as markers of disease activity in childhood-onset systemic lupus erythematosus: a longitudinal cohort study
Rattachement africain : us, nl, se. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVES: Mitochondria are prominent antigenic sources, capable of triggering IFN-induced inflammatory pathways in SLE. Recent studies suggest presence of AMA in LN patients with adult-onset SLE. Whether AMA reflect disease activity in childhood-onset SLE (cSLE) remains unexplored. Here, we present inaugural data on the potential utility of AMA as a biomarker in cSLE. METHODS: Human mitochondria were incubated with serum, and IgG, IgM and IgA binding assessed by flow cytometry. Sera were obtained prospectively from 29 cSLE patients, at two different timepoints (TP), the first (TP-1) representing a state of active disease (SLEDAI ≥4), and the second (TP-2), of clinically quiescent disease (SLEDAI ≤4). IFNα2 serum levels were assessed by single-molecule array. RESULTS: Median age at disease diagnosis was 14.9 ± 3.6 years. Median SLEDAI and prednisone dose were 9.5 and 0.43 mg/kg/day at TP-1, and 2 and 0.14 mg/kg/day at TP-2. Median time interval between TP-1 and TP-2 was of 6 ± 3.7 months. AMA-IgG decreased between TP-1 and TP-2 (P = 0.0426), and correlated positively with SLEDAI (ρ = 0.41, P = 0.026) and anti-dsDNA (ρ = 0.66, P = 0.0001) at TP-1. AMA-IgM oscillated according to disease activity (P = 0.0065), while AMA-IgA remained stable. AMA-IgG and -IgM correlated with IFNα2 levels (ρ = 0.729, P < 0.0001, and ρ = 0.631, P = 0.001, respectively) during active disease. CONCLUSION: AMA-IgG emerges as a promising biomarker of disease activity in cSLE, and its increase is in alignment with elevated IFNα2 expression.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Anti-mitochondrial antibodies as markers of disease activity in childhood-onset systemic lupus erythematosus: a longitudinal cohort study
- Date Crossref
- 23/05/2025
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Washington Division of Rheumatology pays non établi dans la noticeUniversité ou école supérieure
-
Erasmus MC pays non établi dans la noticeÉtablissement de santé
-
Erasmus MC - Sophia Children’s Hospital pays non établi dans la noticeÉtablissement de santé
-
Karolinska University Hospital Department of Medicine pays non établi dans la noticeÉtablissement de santé
-
Karolinska Institutet pays non établi dans la noticeUniversité ou école supérieure
-
Center for Rheumatology pays non établi dans la noticeStructure de recherche
-
Erasmus University Medical Center Department of Immunology pays non établi dans la noticeUniversité ou école supérieure
Division of Rheumatology — University of Washington, Erasmus MC et Erasmus MC - Sophia Children’s Hospital, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.